Analysts’ Recommendations for Almost Family and Peers in March

Almost Family (AFAM) is a leading provider of home healthcare services and related innovations to drive savings for payers and improve patient outcomes. The company operates more than 330 locations across 26 states in the United States.

Almost Family operates three business segments: Home Health, Other Home-Based Services, and Healthcare Innovations.

In March 2018, of the five analysts covering Almost Family, one has given the stock a “strong buy” rating, and four have given it “hold” ratings. The mean rating for the stock is 2.6 with a target price of $61.6.

Of the four analysts covering Addus HomeCare (ADUS) in March 2018, three analysts have given the stock “strong buy” ratings, while one analyst has given it a “hold” rating. The mean rating for the stock is 1.5 with a target price of $45.3.

Of the six analysts covering BioScrip (BIOS) in March 2018, three analysts have given the stock “strong buy” ratings, and three have given it “buy” ratings. The mean rating for the stock is 1.5 with a target price of $3.79.

Of the 18 analysts covering Tenet Healthcare (THC) in March 2018, six analysts have given the stock “buy” or higher ratings, ten analysts have given it “hold” ratings, and two have given it “sell” ratings. The mean rating for the stock is 2.56 with a target price of $22.76.

In the next part of the series, we’ll take a look at the merger between Almost Family and LHC Group (LHCG).